证券代码： 002923 证券简称：润都股份 珠海润都制药股份有限公司投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |-------------------------|-------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动 \n类别 | □ 特定对象调研 \n□ 媒体采访 \n□ 新闻发布会 现场参观 \n□ √ 其他（ 2022 | □ 分析师会议 \n □ ...

珠海润都制药股份有限公司 2022 年第三季度报告 证券代码：002923 证券简称：润都股份 公告编号：2022-056 珠海润都制药股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度报告是否经过审计 □是 否 1 珠海润都制药股份有限公司 2022 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 是 □否 追溯调整或重述原因 其他原因 | | 本报告期 | | 上年同期 | 本报告期 比上年同 | 年初至报 | 上年同期 | | 年初至报 告期末比 上年同期 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | ...

证券代码：002923 证券简称：润都股份 公告编号：2022-052 珠海润都制药股份有限公司 关于参加2022年广东辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，珠海润都制药股份有限公司（以下简称"公 司"）将参加由中国证券监督管理委员会广东监管局、广东上市公司协会共同举办 的 2022 年广东辖区上市公司投资者网上集体接待日活动。 现将有关事项公告如下： 本次投资者网上集体接待日活动将在深圳市全景网络有限公司提供的网上平 台 ， 采 取 网 络 远 程 的 方 式 举 行 。 投 资 者 可 登 录 " 全景路演 " 网 站 （http://rs.p5w.net）参与本次活动，网上互动交流时间为 2022 年 9 月 22 日（星 期四）15:50 至 16:50。 届时公司董事长陈新民先生、董事兼总经理刘杰先生、董事会秘书（代行）兼 副总经理财务总监石深华先生将通过网络在线交流形式与投资者进行沟通交流，欢 迎广大投资者积极参与。 特此公告。 珠海润都制药股份有限公司 董事会 ...

Financial Performance - The company reported a revenue of 1.2 billion RMB for the first half of 2022, representing a year-on-year increase of 15%[1]. - The net profit attributable to shareholders was 300 million RMB, up 20% compared to the same period last year[1]. - The company achieved operating revenue of CNY 658.87 million, representing a 14.68% increase compared to the same period last year[22]. - Net profit attributable to shareholders reached CNY 75.10 million, up 16.28% year-on-year[22]. - The net profit after deducting non-recurring gains and losses was CNY 69.32 million, reflecting a 16.43% increase from the previous year[22]. - The company reported an operating profit of CNY 84.22 million, which is a 19.59% increase compared to the same period last year[32]. - Basic earnings per share for the first half of 2022 were CNY 0.31, consistent with the previous year[22]. - The company’s net profit growth rate for 2021 did not meet the conditions for the release of certain restricted shares, leading to the repurchase of 1,671,950 shares from 190 incentive targets[158]. - The company reported a total comprehensive income of CNY 86,456,016.55, compared to CNY 69,017,148.98 in the previous year, indicating a growth of 25.3%[199]. Market Expansion and Product Development - User data showed an increase in active users by 25%, reaching 5 million by the end of June 2022[1]. - The company plans to launch three new products in the second half of 2022, targeting a market expansion of 30% in the new segments[1]. - The company is focused on expanding its international market presence, contributing to the growth in raw materials and intermediates sales[31]. - The company is investing in the expansion of high-end raw material drug production, with a total investment of ¥8,587,872 planned[77]. - The company has launched 9 enteric-coated and sustained-release formulation products, with multiple projects under research[58]. Research and Development - Research and development expenses increased by 10% to 150 million RMB, focusing on innovative drug formulations[1]. - R&D investment amounted to 4,352.25 million CNY, reflecting a year-on-year increase of 9.81%[34]. - The company submitted 13 patent applications during the reporting period, including 4 invention patents and 4 utility model patents[36]. - Research and development expenses increased to ¥43,522,530.48, up from ¥39,634,607.06, reflecting a focus on innovation[194]. - Research and development expenses increased to CNY 44,624,430.25, compared to CNY 40,946,050.86 in the previous year, reflecting a growth of 9.2%[198]. Financial Management and Liabilities - The total liabilities increased by 10.73% to CNY 882.84 million, resulting in a debt-to-asset ratio of 44.23%, up 2.48 percentage points[31]. - The company reported a significant increase in prepayments, which rose to CNY 43,290,546.50 from CNY 23,020,291.88, representing an increase of approximately 88.5%[186]. - Total liabilities reached CNY 882,839,860.10, up from CNY 797,282,506.70, indicating an increase of about 10.7%[187]. - Long-term borrowings increased significantly to CNY 367,413,340.00 from CNY 250,000,000.00, marking a rise of about 46.9%[187]. - The company reported a net cash flow from operating activities of -¥3,503,174.12, a significant decrease of 123.61% compared to ¥14,835,526.91 in the previous year[66]. Regulatory and Compliance Issues - The company is facing regulatory challenges that may impact its product approval timelines, which are being actively managed[1]. - The company emphasizes strict adherence to GMP standards across all processes to ensure product quality and compliance with new regulations[89]. - The company has established a comprehensive safety management system, achieving no major safety incidents during the reporting period[37]. - The company has implemented measures to ensure wastewater treatment meets the Class A standard as per national regulations, achieving compliance with GB18918-2002[106]. Environmental and Social Responsibility - The company has implemented effective environmental protection measures, ensuring that wastewater treatment meets the standards of the Guangdong Province[102]. - The company has made donations totaling CNY 126,800 to support rural revitalization and improve living conditions in Tibet[121]. - A donation of CNY 95,870 worth of self-produced medicines was made to enhance the medical skills of rural doctors, contributing to poverty alleviation efforts[121]. - The company has compiled its first sustainability report for 2021, focusing on environmental, health, labor, and ethical management[122]. - The company actively engages in social responsibility, aiming to benefit a wide range of stakeholders including shareholders, employees, and the community[115]. Shareholder and Equity Management - The company will not distribute cash dividends or issue bonus shares for this fiscal year[1]. - The company distributed a cash dividend of RMB 4.00 per 10 shares, totaling RMB 74,271,700.00, based on a total share capital of 185,679,250 shares[43]. - The company completed the repurchase and cancellation of 30,400 restricted stocks as part of its stock incentive plan[96]. - The total number of ordinary shareholders at the end of the reporting period was 17,302[169]. - Major shareholders include Li Xi and Chen Xinmin, each holding 29.85% of the shares, totaling 72,047,130 shares[169].

Financial Performance - The company's operating revenue for 2021 was approximately ¥1.19 billion, a decrease of 5.01% compared to ¥1.25 billion in 2020[20]. - Net profit attributable to shareholders for 2021 was approximately ¥139.77 million, an increase of 2.87% from ¥135.86 million in 2020[20]. - The net profit after deducting non-recurring gains and losses was approximately ¥126.63 million, reflecting an increase of 11.33% from ¥113.75 million in 2020[20]. - The net cash flow from operating activities was approximately ¥205.91 million, a decrease of 17.75% compared to ¥250.35 million in 2020[20]. - Total assets at the end of 2021 reached approximately ¥1.91 billion, an increase of 26.14% from ¥1.51 billion at the end of 2020[20]. - The net assets attributable to shareholders at the end of 2021 were approximately ¥1.11 billion, up 7.12% from ¥1.04 billion at the end of 2020[20]. - The basic earnings per share for 2021 was ¥0.76, an increase of 2.70% from ¥0.74 in 2020[20]. - The weighted average return on equity for 2021 was 13.06%, a decrease of 0.75% from 13.81% in 2020[20]. - The company reported a total of ¥16.76 million in government subsidies related to normal business operations in 2021, down from ¥26.88 million in 2020[25]. Risk Management and Governance - The company has detailed various risks and countermeasures in its annual report, ensuring transparency for investors[4]. - The company emphasizes the importance of accurate financial reporting, with key personnel affirming the completeness and truthfulness of the financial statements[3]. - All board members attended the meeting to review the annual report, indicating strong governance practices[4]. - The company has not identified any significant risks that could materially affect its operations during the reporting period[4]. - The company's governance and internal control measures have been strengthened, including the management of 1,839,500 shares of restricted stock for 212 employees[65]. - The company has established a complete corporate governance structure, including a shareholders' meeting, board of directors, supervisory board, and management team, ensuring compliance with relevant laws and regulations[126]. - The actual governance situation of the company aligns with the requirements of the "Code of Corporate Governance for Listed Companies," with no significant discrepancies identified[127]. - The company maintains independence in assets, personnel, finance, organization, and business from its controlling shareholders, ensuring a complete operational system[128]. Research and Development - The company invested CNY 92.14 million in R&D during 2021, focusing on both independent and collaborative development efforts[55]. - The company achieved multiple R&D milestones, including the DMF registration for new drugs such as Carvedilol and Ibuprofen, and completed the technical review for the active pharmaceutical ingredient (API) of Right Levosimendan[56]. - The company submitted 62 patent applications in 2021, including 37 invention patents, and was awarded 30 new patents[58]. - The company is committed to improving its research and development efforts to address the growing demand for innovative and accessible medications[31]. - The company continues to focus on the development of innovative drug formulations and controlled-release technologies[117]. Production and Operations - The company operates several wholly-owned subsidiaries, enhancing its operational capabilities and market reach[11]. - The company has established a complete procurement, production, and sales system, ensuring compliance with GMP standards for both formulation and raw material production[38]. - The company has implemented a contract manufacturing model (CMO) to enhance production capabilities and meet specific client needs[40]. - The company is investing in a new production capacity project for oral solid preparations, targeting an annual output of 6 billion tablets, expected to be operational in 2022[119]. - The company is advancing the construction of the high-end raw material production base in Jingmen, focusing on GMP management and safety production standards[120]. Market Strategy and Sales - The sales strategy combines professional academic promotion with commercial distribution and regional control, enhancing market reach and product availability[39]. - The company aims to become a leading enterprise in the production of microtablet formulations and antihypertensive drugs, aligning with national health strategies[32]. - The company is focused on expanding its market presence and enhancing its product offerings through strategic initiatives[141]. - The company plans to enhance its raw material and pharmaceutical intermediate sales through long-term strategic partnerships and increased market coverage[115]. Environmental and Social Responsibility - The company emphasizes the importance of environmental protection and safety production, implementing systematic and standardized management practices[119]. - The company has implemented effective environmental management measures to treat wastewater, ensuring compliance with the Guangdong Province water pollution discharge standards[200]. - The company has not reported any major environmental violations during the reporting period[199]. - The company is classified as a key pollutant discharge unit by environmental protection authorities[199]. Shareholder Returns and Dividends - The company plans to distribute a cash dividend of 4.00 CNY per 10 shares (including tax) to all shareholders, with no bonus shares issued[4]. - The company has established a clear profit distribution policy, focusing on long-term sustainable development and ensuring reasonable returns for shareholders[172]. - The distributable profit for the company was 519,952,682.64 CNY, after accounting for a statutory surplus reserve of 10% from the net profit of 143,831,378.57 CNY for the year[175]. - The company reported a cash dividend of 4.00 CNY per 10 shares (including tax), with a total cash dividend amounting to 74,271,700 CNY, which represents 100% of the total profit distribution[173]. Employee Management and Training - The total number of employees at the end of the reporting period was 1,594, with 1,136 in the parent company and 458 in major subsidiaries[162]. - The company implemented a comprehensive employee compensation policy consisting of fixed salary, overtime pay, work allowances, seniority allowances, living allowances, holiday bonuses, and year-end performance bonuses[164]. - In 2021, the company conducted 20 new employee training sessions with a total of 353 participants and 2,063 internal training sessions with 55,038 participants[170]. Future Outlook - The company aims to achieve a revenue of CNY 1,442.31 million in 2022, representing a growth of 21.21% compared to the previous year[115]. - The projected net profit for 2022 is CNY 146.34 million, an increase of 4.70% year-over-year[115]. - The company is accelerating the R&D of new raw materials and aims to register products in the EU, the US, Japan, and South Korea[118].

Financial Performance - The company's operating revenue for Q1 2022 was CNY 322,719,191.72, a decrease of 0.43% compared to CNY 324,097,123.51 in the same period last year[4] - Net profit attributable to shareholders increased by 8.79% to CNY 38,124,057.71 from CNY 35,043,698.73 year-on-year[4] - The net profit after deducting non-recurring gains and losses rose by 9.38% to CNY 35,417,281.48 compared to CNY 32,378,567.30 in the previous year[4] - Operating profit for the first quarter was CNY 41,577,682.14, a slight increase from CNY 40,093,005.83 in the previous year, reflecting a growth of 3.7%[19] - Total revenue from sales of goods and services reached CNY 264,507,609.83, compared to CNY 230,956,278.36 in the prior year, marking an increase of 14.6%[22] - The net profit for the first quarter of 2022 was CNY 38,124,057.71, representing an increase of 8.0% compared to CNY 35,043,698.73 in the same period last year[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,975,466,545.59, reflecting a growth of 3.46% from CNY 1,909,438,088.21 at the end of the previous year[4] - Total liabilities at the end of the quarter were CNY 825,158,626.37, compared to CNY 797,282,506.70 at the beginning of the year, indicating an increase of approximately 3.5%[16] - The company's total assets increased to CNY 1,975,466,545.59 from CNY 1,909,438,088.21, reflecting a growth of about 3.5%[16] Cash Flow - The company's cash flow from operating activities improved by 17.27%, with a net outflow of CNY 18,417,173.83 compared to CNY 22,262,319.72 in the same period last year[4] - The cash flow from operating activities showed a net outflow of CNY -18,417,173.83, an improvement from CNY -22,262,319.72 in the same quarter last year[23] - The total cash inflow from financing activities was CNY 107,075,340.00, compared to CNY 179,000,000.00 in the previous year, indicating a decrease of 40.1%[24] - Investment activities resulted in a net cash outflow of CNY -115,496,056.70, worsening from CNY -53,766,585.30 in the same quarter last year[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,623[10] - The company reported a basic and diluted earnings per share of CNY 0.21, up from CNY 0.19 in the same quarter last year[20] Operational Metrics - Total operating costs for Q1 2022 were CNY 283,735,560.59, down from CNY 285,260,907.53 in the previous period, indicating a decrease of about 0.5%[18] - The company's cash and cash equivalents at the end of the quarter were CNY 189,090,940.55, down from CNY 250,301,867.27 at the beginning of the year, reflecting a decrease of approximately 24.4%[14] - Accounts receivable increased to CNY 122,144,942.45 from CNY 114,536,538.93, marking an increase of about 6.3%[14] - Inventory levels rose to CNY 380,668,863.94, compared to CNY 335,527,464.40 at the start of the year, representing an increase of approximately 13.4%[14] Borrowings - Long-term borrowings increased by 42.83% to CNY 357,075,340.00, attributed to financing for ongoing projects[8] - The company experienced a 90.91% reduction in short-term borrowings, decreasing to CNY 3,000,000.00 from CNY 33,000,000.00[8] - Short-term borrowings decreased significantly from CNY 33,000,000.00 to CNY 3,000,000.00, a reduction of about 90.9%[15] Research and Development - Research and development expenses increased to CNY 21,615,040.10, up 14.8% from CNY 18,827,629.40 year-over-year[19] Strategic Focus - The company continues to focus on expanding its product offerings and market presence, although specific new products or technologies were not detailed in the report[13]

珠海润都制药股份有限公司 2021 年第三季度报告 2021 年第三季度报告 2021 Third quarter report | 证 券 代 码 ： 00 2 92 3 | | --- | | 证 券 简 称 ： 润 都 股 份 | | 公 告 编 号 ： 20 2 1 -07 1 | 1 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中 财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 珠海润都制药股份有限公司 2021 年第三季度报告 证券代码：002923 证券简称：润都股份 公告编号：2021-071 珠海润都制药股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | ...

Financial Performance - The company reported a revenue of 500 million RMB for the first half of 2021, representing a year-on-year increase of 20%[16] - The net profit attributable to shareholders was 100 million RMB, up 15% compared to the same period last year[16] - The company reported a revenue of CNY 574.53 million for the first half of 2021, a decrease of 12.31% compared to CNY 655.17 million in the same period last year[22] - Net profit attributable to shareholders was CNY 64.58 million, down 15.43% from CNY 76.36 million year-on-year[22] - The company's operating revenue for the reporting period was ¥574,528,206.81, a decrease of 12.31% compared to ¥655,167,963.35 in the previous year, primarily due to macro policies, the pandemic, and product price fluctuations[46] - The company reported a significant decrease in cash flow from operating activities, which was ¥14,835,526.91, down 84.32% from ¥94,598,098.95 in the previous year, due to increased production scale and reduced current liabilities[46] - The total comprehensive income for the first half of 2021 was CNY 69.02 million, compared to CNY 77.28 million in the same period of 2020[168] Research and Development - The company plans to invest 50 million RMB in R&D for new drug development in the next fiscal year[16] - The company is focusing on the development of a new drug that targets chronic diseases, with clinical trials expected to begin in Q4 2021[16] - The company has established a strategic partnership with a leading research institution to enhance its R&D capabilities[16] - The company's R&D investment decreased by 18.30% to ¥39,634,607.06 from ¥48,513,233.03, attributed to the stage of ongoing R&D projects and fluctuations in clinical research costs[46] - The company aims to improve its R&D efficiency and core technology capabilities by adopting diversified R&D management models and attracting high-level R&D talent[68] Market Expansion - User data indicates a 30% increase in the number of active patients using the company's products[16] - The company has expanded its market presence by entering three new provinces, increasing its distribution network by 25%[16] - Future guidance estimates a revenue growth of 25% for the next half of the year, driven by new product launches[16] - The company is exploring potential acquisition opportunities to further expand its product portfolio and market reach[16] Production and Operations - The company is focusing on enhancing safety production, quality optimization, and implementing a multi-channel marketing strategy to penetrate broader markets[32] - The company has accelerated the clinical research of its innovative drug, and multiple products have been submitted for drug registration in the US, EU, Japan, and South Korea[31] - The company is advancing the construction of its "Formulation Workshop Capacity Upgrade Project" and has spent approximately CNY 263 million on the project as of June 2021[33] - The company is focused on enhancing production efficiency through automation and improving production management to meet annual production targets[34] - The company aims to expand its production capacity for active pharmaceutical ingredients and formulations to seize market opportunities and improve profitability[34] Financial Position - The total assets of the company increased by 9.08% to CNY 1.65 billion compared to the end of the previous year[22] - The net assets attributable to shareholders rose by 0.92% to CNY 1.05 billion[22] - The company's long-term borrowings increased significantly to CNY 240,000,000.00, reflecting a rise of 14.39% in proportion to total assets due to project financing[52] - The company's total liabilities decreased from CNY 475,538,501.01 at the end of 2020 to CNY 603,381,088.31, representing an increase of approximately 26.8%[155] Environmental and Social Responsibility - The company has implemented effective environmental management measures, ensuring wastewater treatment meets the standards set by the Guangdong Province and the pharmaceutical industry[84] - The company has upgraded its hazardous waste storage facilities in compliance with national standards[85] - The company has actively participated in public welfare activities, donating 750,000 RMB for poverty alleviation and rural revitalization projects during the reporting period[99] - The company has established a comprehensive employee rights protection system, ensuring compliance with labor laws and enhancing employee welfare[97] Shareholder and Corporate Governance - The company has developed a shareholder dividend return plan for 2020-2022, emphasizing the protection of shareholder and creditor rights[93] - The company held three shareholder meetings during the reporting period, with participation rates of 63.25% on January 28, 2021, 63.06% on May 18, 2021, and 63.53% on June 25, 2021[73][75][77] - The company plans not to distribute cash dividends or issue bonus shares for the semi-annual period[75] - The company reported a rental expense of 0.877 million yuan for office space in Guangzhou and 0.9713 million yuan for office space in Wuhan during the reporting period[118] Compliance and Legal Matters - The semi-annual financial report was not audited[107] - There were no significant litigation or arbitration matters during the reporting period[108] - The company did not have any violations regarding external guarantees during the reporting period[106] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[105]

Financial Performance - The company's operating revenue for 2020 was CNY 1,252,630,836.95, a decrease of 7.89% compared to CNY 1,359,908,295.50 in 2019[18]. - The net profit attributable to shareholders in 2020 was CNY 135,862,411.12, an increase of 14.27% from CNY 118,896,727.79 in 2019[18]. - The net profit after deducting non-recurring gains and losses was CNY 113,745,137.62, up 27.38% from CNY 89,294,936.87 in 2019[18]. - The net cash flow from operating activities increased by 65.46% to CNY 250,346,177.78 in 2020, compared to CNY 151,299,880.47 in 2019[18]. - The total assets at the end of 2020 were CNY 1,513,772,150.91, reflecting a 14.10% increase from CNY 1,326,680,483.36 at the end of 2019[19]. - The basic earnings per share for 2020 was CNY 0.74, representing a 15.63% increase from CNY 0.64 in 2019[18]. - The weighted average return on equity was 13.81% in 2020, slightly up from 13.28% in 2019[18]. - The company reported a total of CNY 22,117,273.50 in non-recurring gains for 2020, down from CNY 29,601,790.92 in 2019[24]. Dividend Distribution - The company plans to distribute a cash dividend of 4.00 CNY per 10 shares, amounting to an estimated total cash dividend of 74.35 million CNY based on a total share capital of 185.87 million shares[5]. - The cash dividend for 2020 represents 54.72% of the net profit attributable to the parent company, which was 135,862,411.12 CNY[116]. - The actual distributable profit for the parent company in 2020 was CNY 464,642,581.93, with a proposed cash dividend of CNY 4.00 per 10 shares, amounting to an estimated total cash dividend of CNY 74,347,840[118]. - The cash dividend policy has been confirmed to comply with the company's articles of association and shareholder resolutions[114]. Risk Management - The board of directors confirmed that there are no significant risks affecting the company's operations during the reporting period[5]. - The company has outlined various risks and countermeasures in the annual report, which investors are encouraged to review[5]. - The company has faced risks related to fundraising investment projects due to potential policy and market changes, which could impact expected returns[108]. - The company has implemented measures to strengthen fundraising management and adjust investment projects in response to market conditions[108]. Research and Development - The company has established a research institute in Wuhan to enhance its research and development capabilities[9]. - The company invested ¥102.47 million in R&D during 2020, focusing on both independent and collaborative development projects[45]. - The company’s R&D efforts focus on innovative drug delivery systems, with 9 enteric-coated and sustained-release products already on the market[37]. - The company plans to strengthen its R&D capabilities by increasing investment and accelerating the development of innovative drugs[103]. Market Strategy - The company is focused on expanding its market presence and developing new products to meet consumer needs[10]. - The company aims to enhance its core competitiveness and expand both domestic and international markets, focusing on raw materials and preparations[99]. - The company will implement a macro marketing strategy for formulations, focusing on six core product areas and expanding marketing channels[102]. Production and Operations - The company is committed to adhering to Good Manufacturing Practice (GMP) standards in its production processes[10]. - The company has a well-defined procurement, production, and sales model, ensuring quality control and market responsiveness[29]. - The company has developed a complete industrial chain from raw materials to formulations, enhancing its market competitiveness[37]. - The company’s Zhuhai plant covers an area of 112,900 square meters, with fixed asset additions of about ¥160 million in 2020[50]. Environmental and Social Responsibility - The company has been recognized as a national green factory, adhering to environmental management standards and achieving compliance in pollutant emissions[150][158]. - The company actively participated in social responsibility initiatives, contributing 100,000 RMB to support education in poverty-stricken areas[154]. - The company has invested 66.92 million RMB in various poverty alleviation efforts, including educational support for underprivileged students[155]. Shareholder Information - The company has established a shareholder return plan for 2020-2022, emphasizing the protection of shareholder rights and interests[149]. - Major shareholders include Li Xi and Chen Xinmin, each holding 29.81% of the shares, totaling 55,420,875 shares[188]. - The company’s total number of restricted shares released for trading during the reporting period was 2,167,800 shares[178]. - The company has implemented a stock incentive plan for 106 individuals, which will increase liabilities until the options are exercised[186]. Compliance and Governance - The company did not experience any significant accounting errors requiring restatement during the reporting period[126]. - There were no changes in the scope of the consolidated financial statements compared to the previous year[127]. - The company did not engage in any major litigation or arbitration during the reporting period[129]. - The company has no major guarantees or entrusted loans during the reporting period[144][147].

Revenue and Profit - The company's revenue for Q1 2021 was ¥324,097,123.51, representing a 2.00% increase compared to ¥317,755,476.17 in the same period last year[7] - Net profit attributable to shareholders was ¥35,043,698.73, up 9.61% from ¥31,971,613.75 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥32,378,567.30, reflecting a 15.51% increase from ¥28,031,016.40 in the previous year[7] - Basic earnings per share for the period were ¥0.19, a 5.56% increase from ¥0.18 in the same period last year[7] - The company reported a total comprehensive income of CNY 35,043,698.73 for Q1 2021, compared to CNY 31,971,613.75 in the previous period[45] - The net profit for the first quarter of 2021 was CNY 38,288,688.09, an increase from CNY 37,716,011.97 in the same period last year, representing a growth of approximately 1.52%[48] - The total profit for the quarter reached CNY 44,661,321.46, up from CNY 41,326,202.35, reflecting a growth of approximately 8.00%[48] Cash Flow - The net cash flow from operating activities was -¥22,262,319.72, a significant decrease of 139.48% compared to ¥56,392,334.38 in the same period last year[7] - Cash flow from operating activities showed a net outflow of CNY -22,262,319.72, a significant decrease compared to a net inflow of CNY 56,392,334.38 in the previous year[52] - The company reported cash inflow from operating activities of CNY 239,807,630.11, down from CNY 275,882,551.27 in the previous year, indicating a decline of approximately 13.06%[52] - The company's operating cash outflow totaled CNY 262,069,949.83, compared to CNY 219,490,216.89 in the previous year, indicating an increase of approximately 19.30%[52] - The company reported a net cash outflow from financing activities of -2,512,121.27 CNY in Q1 2021, compared to a net inflow of 53,029,058.49 CNY in Q1 2020[56] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,625,348,353.61, an increase of 7.37% from ¥1,513,772,150.91 at the end of the previous year[7] - The net assets attributable to shareholders were ¥1,075,360,811.10, up 3.58% from ¥1,038,233,649.90 at the end of the previous year[7] - Total liabilities decreased to CNY 549,987,542.51 from CNY 475,538,501.01, a reduction of about 15.59%[36] - The company's equity increased to CNY 1,075,360,811.10 from CNY 1,038,233,649.90, showing a growth of approximately 3.58%[37] - Total liabilities decreased to CNY 307,749,914.22 from CNY 332,328,549.23[43] Investments and Expenses - The company received government subsidies amounting to ¥3,059,777.30 during the reporting period[8] - Research and development expenses for Q1 2021 were CNY 18,827,629.40, down from CNY 24,089,902.58 in the previous period, indicating a reduction of approximately 21.7%[43] - Sales expenses decreased to CNY 118,782,245.60 from CNY 121,338,018.14, a decline of about 2.1%[43] - The company reported an 84.04% decrease in investment income to ¥165,011.74, mainly due to reduced wealth management returns[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,846[11] - The total amount of funds raised from the public offering was ¥425,250,000.00, with a net amount of ¥345,610,300.00 after deducting issuance costs[24] Other Financial Metrics - The weighted average return on equity remained stable at 3.33%[7] - The company has a remaining balance of raised funds of ¥60,921,110.25, including interest income and wealth management returns[24] - The solid preparation workshop renovation project has achieved an investment progress of 72.89% as of March 31, 2021[24]